Exchange: NASDAQ·Updated 07:38 PM EST
ORKA logo

ORKA Oruka Therapeutics Inc.

$97.00
$1.76
(1.80%)
Today
Closed $95.81
$1.19
(1.24%)
After Hours
Reported EarningsNov 9
Mkt Cap$6.5B
Vol1.98M

About ORKA

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
46

Neutral Sentiment

How do you feel about ORKA?

Merlintrader
Oruka $ORKA will present at four investor conferences in November. Guggenheim Nov 10, Stifel Nov 11, UBS Nov 17 and Jefferies Nov 18. Shares closed at $95.43 on Monday, above the SMA50 and above the SMA200, RSI 64. More details in our hub. Not investment advice.
2
Rayvio_News_Filter
$ORKA 🏥 Oruka Therapeutics, Inc. reported EVERLAST-B Week 16 results for ORKA-001 showing 61% PASI 100 and 86% PASI 90 in the high-dose group, and EVERLAST-A responses deepening to 71% PASI 100 at Week 28. Market-relevant event
1
thesheiktrader
$ORKA noviembre will be crucial, we can have one best performance on the year before the results of 52 week
1
Whiskeyunderthebed
$ORKA Great data so far with 001-looking forward to the -002 data release and the initiation of -004. Blockbuster!
1
BiotechSwings
Today on the calendar: $ORKA drops Phase 2b psoriasis data this morning, $IOVA presents lifileucel sarcoma data, and the BOLT financing is set to close and the week ahead is all about Friday, $INO has its Oct 30 date for INO 3107 and $AGIO follows Nov 1 for mitapivat in sickle cell, Sunday date so Friday is the real window
1
focafoca99
$ORKA will host a conference call to present Week 16 data from its EVERLAST-B Phase 2b trial on Oct 26.
1
Quantumup
Jefferies reiterated $ORKA Buy-$133 and said--Bottom line. '001 thesis remains intact, w/ mgmt providing helpful framing for the Dec '26 W52 readout. [ $UCBJY ABBV PTGX JNJ SYRE ABVX NVS BMY TAK] Mgmt sees ~50%+ of pts maintaining PASI 100 on Q12M as compelling, while emphasizing PASI 100 is a stringent bar and pts w/ minimal breakthrough disease could still prefer annual dosing, potentially broadening the commercially relevant Q12M population. Beyond '001, '002 is shaping up as the next key value driver, targeting Bimzelx-like efficacy/ tolerability + Q6M dosing in PsO, w/ Ph2 data 1Q27. Bigger picture, ORKA is evolving beyond the '001/Q12M story into a broader long-acting I&I franchise, w/ '002 adding a 2nd value driver and ~$1.2B cash supporting '001 through BLA + '002 into pivotal development.
shoc24
$ORKA is ranked #18 in healthcare momentum with a score of 84. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
Ian_FV
6-K/8-K Important Update $ORKA Oruka Therapeutics, Inc. reported positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001, an investigational IL-23p19 monoclonal antibody, for moderate-to-severe plaque psoriasis. In the trial, 61% of patients receiving 600 mg achieved PASI 100, significantly surpassing the placebo group (p<0.0001). The company plans to commence Phase 3 trials in early 2027 and anticipates releasing 52-week results in December 2026.
Ian_FV
6-K/8-K Important Update $ORKA Oruka Therapeutics, Inc. reported positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001, an investigational IL-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis. In the trial, 61% of patients receiving 600 mg achieved PASI 100, significantly outperforming the placebo group (p<0.0001), with a favorable safety profile noted. The company intends to begin Phase 3 trials in early 2027, pending regulatory discussions.
Rayvio_News_Filter
$ORKA 🏥 Oruka Therapeutics, Inc. announced Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in 187 patients with moderate-to-severe psoriasis, with PASI 100 at Week 16 as the primary endpoint. Prioritized by relevance
filecrux
$ORKA Oruka's 600 mg psoriasis dose cleared skin in 61% at Week 16 with no serious side effects. 🏢 Oruka Therapeutics is a clinical-stage biotech developing ORKA-001, a long-acting IL-23p19 antibody for psoriasis meant to be dosed once or twice a year 📈 That is the dose Oruka plans to take into Phase 3, and 61% of its patients reached fully clear skin (PASI 100) versus 0% on placebo (p<0.0001), close to the 63.5% EVERLAST-A showed in April 🏦 Oruka held $1.13B in cash and investments at June 30, 2026, against a roughly $5.31B market value at $80.15 (16:00 ET, Oct 23, 2026) ⚠️ The bear case is that 16 weeks cannot prove the durability behind once-a-year dosing, the mid dose nearly matched on PASI 90 (85% vs 86%), and Phase 3 still waits on regulator talks 📅 Next: EVERLAST-A 52-week results in December 2026, then ORKA-002's ORCA-SURGE Week 16 data in 1Q 2027 Source: GlobeNewswire release, Oct 26 + SEC 8-K, Aug 10
Rayvio_News_Filter
$ORKA 🏥 Oruka Therapeutics, Inc. announced positive Week 16 EVERLAST-B results for ORKA-001 in moderate-to-severe psoriasis, with 61% PASI 100 and 86% PASI 90 in the 600 mg high-dose group. Prioritized by relevance
AlertsAndNews
$ORKA Data release coming here tomorrow. Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 "today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results."

Advertisement|Remove ads.